TAMPA, Fla.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global leader in advancing surgical innovation, and AdventHealth Tampa today announced that AdventHealth Tampa will realize approximately $200,000 in annual savings through its involvement in Baxter’s Vital Edge program. Vital Edge is a data-driven, evidence-based intraoperative hemostasis management program designed to help hospitals and health care providers improve hemostasis utilization practices impacting three interconnected areas of surgical care: clinical efficacy, operational efficiency and financial performance.
“We know patients have a choice when it comes to care, and at AdventHealth Tampa we are committed to providing patients with our clinical expertise in the safest environment possible,” said Denyse Bales-Chubb, president and chief executive officer at AdventHealth Tampa. “We appreciate the ability to work with Baxter to provide additional opportunities in how we innovate and provide exceptional care for the communities we serve.”
Bleeding during surgery can lead to increased complications, including surgical revisions and transfusions, which may result in higher resource utilization and costs.1 2 In a retrospective analysis of 25,048 surgeries performed in the United States, uncontrolled bleeding events occurred in nearly 57% of the procedures across multiple surgical interventions.3 These considerations, as well as current shortages of blood and blood products due to the COVID-19 pandemic, have led to a growing focus on patient blood management in hospitals nationwide.
Through Vital Edge, Baxter’s Advanced Surgery team partners with hospitals to identify and educate on opportunities to optimize utilization of hemostatic agents to reduce intraoperative blood loss and product waste, enhance outcomes and lower costs. The program incorporates educational resources on hemostats, industry-leading clinical expertise and sophisticated health economics tools to help provide hospitals with quantitative data and qualitative insights into their current use of hemostatic agents and the corresponding potential financial impact on their current practices. These findings help maximize clinical and economic value for the hospital.
“Patient blood management is a critical component of delivering high quality care at a lower cost, especially in today’s constantly evolving environment,” said Wil Boren, president of Baxter’s Advanced Surgery business. “We are proud to collaborate with AdventHealth Tampa through our Vital Edge program to create tailored hemostasis strategies that support their clinical, operational and financial goals.”
About Baxter
Every day, millions of patients and caregivers rely on Baxter’s leading portfolio of critical care, nutrition, renal, hospital and surgical products. For more than 85 years, we’ve been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers that make it happen. With products, technologies and therapies available in more than 100 countries, Baxter’s employees worldwide are now building upon the company’s rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations. To learn more, visit www.baxter.com and follow us on Twitter, LinkedIn and Facebook.
About AdventHealth West Florida Division
The West Florida Division of AdventHealth has some of the nation’s brightest medical minds making lifesaving breakthroughs with surgical pioneers, scientists and researchers using leading edge technology and innovation to deliver our brand of whole-person care. Our network of care includes AdventHealth Carrollwood, AdventHealth Connerton, AdventHealth Dade City, AdventHealth Lake Placid, AdventHealth North Pinellas, AdventHealth Ocala, AdventHealth Sebring, AdventHealth Tampa, AdventHealth Wauchula, AdventHealth Wesley Chapel and AdventHealth Zephyrhills, as well as five freestanding offsite Emergency Rooms including AdventHealth Brandon ER, AdventHealth Central Pasco ER, AdventHealth Palm Harbor ER, AdventHealth TimberRidge ER, and AdventHealth Westchase ER. We are more than hospitals, as we have a robust system of care including specialty acute care, over 200 primary care and specialty employed physicians, Express Care at Walgreens clinics, urgent care centers, wound care, physical therapy, home care, mobile mammography and more. AdventHealth is a faith-based not-for-profit health care system with a mission of Extending the Healing Ministry of Christ. AdventHealth has hundreds of care sites and nearly 50 hospitals across the United States. For more information about AdventHealth, visit AdventHealth.com, or Facebook.com/AdventHealth, and for West Florida Division, click here.
This release includes forward-looking statements concerning the Vital Edge program, including potential benefits associated with its use. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: satisfaction of regulatory and other requirements; actions of regulatory bodies and other governmental authorities; product quality, manufacturing or supply, or patient safety issues; changes in law and regulations; and other risks identified in Baxter's most recent filing on Form 10-K and other SEC filings, all of which are available on Baxter's website. Baxter does not undertake to update its forward-looking statements.
Baxter is a registered trademark of Baxter International Inc.
1 Stokes ME, Ye X, Shah M, Mercaldi K, Reynolds MW, Rupnow MF, Hammond J. Impact of bleeding-related complications and/or blood product transfusions on hospital costs in inpatient surgical patients. BMC Health Serv Res. 2011 May 31;11:135. doi: 10.1186/1472-6963-11-135. PMID: 21627788; PMCID: PMC3126703.
2 Floseal Instructions for Use
3 Corral M, Ferko N, Hollmann S, Broder MS, Chang E. Health and economic outcomes associated with uncontrolled surgical bleeding: a retrospective analysis of the Premier Perspectives Database. Clinicoecon Outcomes Res. 2015 Jul 22;7:409-21. doi: 10.2147/CEOR.S86369. PMID: 26229495; PMCID: PMC4516034.
